The industry is increasingly engaging in collaborations to gain access to technology, such as AI, which is being touted as a potential solution to some of the most challenging aspects of running clinical trials.
Ignoring pediatric considerations is no longer an option for the development of new medicines – though clinical trials in children are still not widely accepted by society, explains industry executive.
“Arbitrary upper age limits for trial entry are almost never justified,” says FDA, which has renewed its efforts to include older adults in clinical trials and tackle some of the key enrollment challenges.
While senior citizens consume roughly one third of all medications – and make up only 13% of the population – factors that complicate geriatric clinical trials leave gaps in knowledge and developments.
It has been nearly 20 years since a currently available drug was tested and approved specifically for the newborn population, say industry experts who are calling for education and policy changes to address the needs of this special patient population.
WCG and InformedDNA have established a new center for genetics and precision medicine in clinical trials – the increasing complexity of which, while potentially daunting, also creates the opportunity for transformational value, say industry experts.
The Scientist.com and HealthEconomics.com partnership connects real-world evidence (RWE) and health economic outcomes research (HEOR) sponsors and providers to help democratize pharmaceutical research, says company exec.
The Russia-based CRO Atlant Clinical has received certification in the organization and management of clinical trials – demand for which continues to increase despite political and economic challenges.